The test is approved to identify patients eligible for Hernexeos, an orally administered targeted treatment for HER2 (ERBB2)-mutant non-small cell lung cancer.
Read More
The liquid biopsy test uses circulating tumor DNA to support therapy selection, trial matching, and monitoring—even when tissue is limited.
Read More
The kit supports both manual and automated workflows to reproducibly isolate high molecular weight DNA suitable for long-read sequencing.
Read More
Several manufacturers have developed advanced multiplex molecular panels in 2025, designed to detect co-infections in a single run.
Read More
Rapid immunoassays have emerged as a valuable tool for providing quick information that can be crucial in life-threatening situations.
Read More